Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Please pick up your Audience Response Keypad in the back of the room Audience Response Questions Using Your Keypad • Questions will be displayed along with the possible answers • When the countdown clock appears, press and release the button that best represents your answer • Your last answer will be recorded • Speed and accuracy count • There is no need to press “GO” or “?” • Please turn in the keypad before you leave for the day. Question # 1 The major goal of HPS3-TIMI 55/REVEAL is to determine if anacetrapib: a) Raises HDL b) Reduces the size of coronary plaques c) Reduces the composite endpoint of coronary death, MI, or coronary revascularization 68% 32% 0% a) b) c) Question # 2 Anacetrapib works by: 80% a) Reducing hepatic cholesterol synthesis b) Inhibiting cholesteryl ester transfer protein c) Reducing absorption of cholesterol 18% 2% a) b) c) Question # 3 Which type of patient history below would NOT be eligible for REVEAL? A. History of prior PCI for angina B. History of myocardial infarction C. History of stroke D. History of peripheral arterial bypass surgery E. History of diabetes mellitus and prior PCI 85% 6% 9% 0% 0% A. B. C. D. E. Question # 4 Which of the following patients would NOT be eligible? 100% a) 50 M with prior MI b) 85 M with prior MI c) 65 M with diabetes and a prior PCI d) 45 F with diabetes, prior MI, and prior stroke 0% a) 0% b) 0% c) d) Question # 5 A subject should be EXCLUDED from REVEAL if: 100% a) PCI is planned in the next 6 months b) If they require dialysis c) If they had a history of rhabdomyolysis following statin treatment d) Any of the above 0% a) 0% b) 0% c) d) Question # 6 Anacetrapib’s effects include all EXCEPT? 96% a) Raising HDL b) Lowering LDL c) Raising blood pressure 0% a) 4% b) c) Let’s Check the Standings… Participant Leader Board 579.03 Participant 1C8658 562.61 562.23 554.59 542 Participant C4E88 Participant 1C853C Participant 15DB4C Participant 15E5B5 536.83 525.57 508.13 Participant 8360B Participant C4E03 Participant 15DB8E 500 500 Participant 169D06 Participant C4EE2 Question # 7 The most effective way to monitor and prevent for possible myositis/ rhabdomyolysis symptoms: a) Measure CPK periodically b) Carefully monitor symptoms of muscle aches c) Review concomitant medications for excluded medications d) All of the above 92% 2% a) 4% b) 2% c) d) Question # 8 What procedures are NOT done at the Screening visit? a) Confirm eligibility b) Informed consent c) Blood pressure and blood tests d) Randomization to anacetrapib or placebo 98% 0% a) 0% b) 2% c) d) Question # 9 Which of the following malignancies is an EXCLUSION criterion at screening: a) Surgery for colon cancer 7 years ago. No evidence of recurrence b) Basal cell carcinoma 3 years ago. c) Hysterectomy for endometrial cancer 10 years ago. No evidence of recurrence. d) Hysterectomy for endometrial cancer 3 years ago. No evidence of recurrence. 76% 20% 4% a) 0% b) c) d) Question # 10 What Procedures are done at the Follow-up Visits? a) Record All SAEs and non-serious AEs (including asking about Unexplained muscle pain or weakness) b) Assess compliance with study drug treatment c) Measure blood pressure and safety bloods d) Issue study treatment (7 month supply) e) Schedule next follow-up appointment f) All of the above 100% 0% 0% a) b) 0% 0% 0% c) d) e) f) Question # 11 A subject who has been off study drug for 1 year due to prolonged illness would like to restart the study drug. What should the site do? 79% a) Patient can not resume study drug because they have been off for >3 months b) The site should rerandomize the patient c) The site can restart the study drug d) The site should have the patient re-sign the original consent form 15% 6% 0% a) b) c) d) Question # 12 A patient who is admitted to the hospital with chest pain, who is found to have non-cardiac chest pain. Should this be reported as an SAE? 96% a) Yes b) No 4% a) b) Participant Leader Board 1142 Linda Lombardo 1121.2 1100 1099.14 1087.38 Barbara Miller Angela Anderson Allison Bohn Laura Armstrong 1083.97 1077.83 1077.09 Cynthia Tremblay Sheila Lehmann Devona Chun-Furlong 1074.59 1070.84 Ann Galla Antoinette (Toni) Rizzo Please Return your Audience Response Keypad as you leave the room